Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series

Clinical Rheumatology

Volumn 34, Issue 2, 2015, Pages 371-377

  Basnayake, Chaminda ^a   Cash, Kathy ^b   Blumbergs, Peter ^b   Limaye, Vidya ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Antibodies; Dermatomyositis; Myositis; Polymyositis; Rituximab

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PREDNISOLONE; RITUXIMAB;

ADULT; AGED; CASE REPORT; FEMALE; HUMAN; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MYOSITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MYOSITIS; PREDNISOLONE; TREATMENT OUTCOME;

EID: 84937732785     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2449-2     Document Type: Review

References (31)

1. Choy EHS, Isenberg DA (2002) Treatment of dermatomyositis and polymyositis. Rheumatology 41:7–13
2. Oddis CV, Conte CG, Steen VD, Medsger TA Jr (1990) Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963–1982. J Rheumatol 17:1329–1334
3. Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971–982
4. Danielsson O, Lindvall B, Gati I, Ernerudh J (2013) Classification and diagnostic investigation in inflammatory myopathies: study of 99 patients. J Rheumatol 40(5):550–564
5. Engel A, Hohlfield R, Banker B (1994) The polymyositis and dermatomyositis syndromes. In: Engel A, Armstrong C (eds) Myology. McGraw-Hill, New York, pp 1335–1383
6. Plotz PH, Rider LG, Targoff IN, Raben N, O’Hanlon TP, Miller FW (1995) Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 122:715–724
7. Casciola-Rosena L, Mammen AL (2012) Myositis autoantibodies. Curr Opin Rheumatol 24:602–608
8. Engel AG, Arahata K (1986) Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 17:704–721
9. Aggarwal R, Oddis CV (2012) Therapeutic advances in myositis. Curr Opin Rheumatol 24:635–641
10. Henriksson KG, Lindvall B (1990) Polymyositis and dermatomyositis 1990: diagnosis, treatment and prognosis. Prog Neurobiol 35:181–193
11. Schiopu E, Phillips K, Macdonald PM, Crofford LJ, Somers EC (2012) Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther 14:R22
12. Yu KH, Wu YJ, Kuo CF, See LC, Shen YM, Chang HC et al (2011) Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol 30:1595–1601
13. Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG (1980) Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med 92:365–369
14. Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL et al (1998) Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 41:392–399
15. Wedderburn LR, Rider LG (2009) Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment: best practice & research. Clin Rheumatol 23:665–678
16. Cronin ME, Miller FW, Hicks JE, Dalakas M, Plotz PH (1989) The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 16:1225–1228
17. Takada K, Nagasaka K, Miyasaka N (2005) Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 38:383–392
18. Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J et al (2000) Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29:95–102
19. Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A, Piani M et al (2002) Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 61:37–41
20. Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A et al (1991) Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 91:162–168
21. Arkfeld DG (2008) The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int 28:205–215
22. Levesque MC, St Clair EW (2008) B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol 121:13–21
23. Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL, Vonk MC (2011) Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology 50:2206–2213
24. Chung L, Genovese MC, Fiorentino DF (2007) A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143:763–767
25. Limaye V, Hissaria P, Liew CL, Koszyk (2012) Efficacy of rituximab in refractory antisynthetase syndrome. B Intern Med J 42(3):e4–e7
26. [No authors listed] (2006) Rituximab for rheumatoid arthritis. Med Lett Drugs Ther 48:34
27. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8:140
28. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J et al (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56(12):3896–3908
29. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 14:2793–2806. doi:10.1002/art.22025
30. Van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann R, Furst DE (2010) Long term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37:558–567
31. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, RIM Study Group (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized placebo-phase trial. Arthritis Rheum 65(2):314–324. doi:10.1002/art.37754